{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:47:03Z","timestamp":1789138023684,"version":"build-2803163510"},"reference-count":38,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002081","name":"Irish Research Council","doi-asserted-by":"publisher","award":["GOIPD\/2021\/276"],"award-info":[{"award-number":["GOIPD\/2021\/276"]}],"id":[{"id":"10.13039\/501100002081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Huntington\u2019s disease (HD) is a progressive inherited neurodegenerative disease caused by a CAG repeat expansion in the huntingtin gene, which is translated into the pathologic mutant huntingtin (mHTT) protein. Despite the great potential of HTT lowering strategies and the numerous antisense oligonucleotides (ASOs) in pre- and clinical trials, sustained silencing of mHTT has not been achieved. As a strategy to improve ASO delivery, cyclodextrin-based nanoparticles (CDs) offer a promising approach. Here, three CDs with distinct chemical structures were designed and their efficacies were compared as potential platforms for the delivery of ASO targeting HTT. Results using striatal neurons and HD patient-derived fibroblasts indicate that modified \u03b3-CDs exhibited the best uptake efficiency and successfully downregulated mHTT at protein and allele levels. The incorporation of the brain-targeting peptide RVG into the modified \u03b3-CDs showed greater downregulation of mHTT protein and HD-causing allele SNP1 than untargeted ones in an in vitro blood\u2013brain barrier model. Although the ASO sequence was designed as a nonallele-specific therapeutic approach, our strategy gives an additional benefit of some mHTT selectivity. Overall, this study demonstrated the CD platform\u2019s feasibility for delivering ASO-based therapeutics for HD treatment.<\/jats:p>","DOI":"10.3390\/pharmaceutics15020520","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T04:25:28Z","timestamp":1675657528000},"page":"520","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cyclodextrin-Based Nanoparticles for Delivery of Antisense Oligonucleotides Targeting Huntingtin"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8129-2150","authenticated-orcid":false,"given":"Monique C. P.","family":"Mendon\u00e7a","sequence":"first","affiliation":[{"name":"Phamacodelivery Group, School of Pharmacy, University College Cork, T12 YT20 Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Sun","sequence":"additional","affiliation":[{"name":"Phamacodelivery Group, School of Pharmacy, University College Cork, T12 YT20 Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Cronin","sequence":"additional","affiliation":[{"name":"Phamacodelivery Group, School of Pharmacy, University College Cork, T12 YT20 Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9693-7022","authenticated-orcid":false,"given":"Andrew J.","family":"Lindsay","sequence":"additional","affiliation":[{"name":"Membrane Trafficking & Disease Laboratory, School of Biochemistry & Cell Biology, Biosciences Institute, University College Cork, T12 YT20 Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5887-2723","authenticated-orcid":false,"given":"John F.","family":"Cryan","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland, University College Cork, T12 YT20 Cork, Ireland"},{"name":"Department of Anatomy and Neuroscience, University College Cork, T12 XF62 Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitriona M.","family":"O\u2019Driscoll","sequence":"additional","affiliation":[{"name":"Phamacodelivery Group, School of Pharmacy, University College Cork, T12 YT20 Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s Disease: A Clinical Review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"785703","DOI":"10.3389\/fncel.2021.785703","article-title":"Innovative Therapeutic Approaches for Huntington\u2019s Disease: From Nucleic Acids to GPCR-Targeting Small Molecules","volume":"15","author":"Komatsu","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"ref_3","first-page":"1068","article-title":"Molecular Strategies to Target Protein Aggregation in Huntington\u2019s Disease","volume":"8","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The Biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"ref_5","first-page":"3","article-title":"The Effects of Huntingtin-Lowering: What Do We Know so Far?","volume":"9","author":"Kaemmerer","year":"2019","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-170235","article-title":"Is Huntingtin Dispensable in the Adult Brain?","volume":"6","author":"Liu","year":"2017","journal-title":"J. Huntingt. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.omtm.2020.09.003","article-title":"Investigational Assay for Haplotype Phasing of the Huntingtin Gene","volume":"19","author":"Svrzikapa","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/JHD-229002","article-title":"Huntington\u2019s Disease Clinical Trials Corner: April 2022","volume":"11","author":"Rodrigues","year":"2022","journal-title":"J. Huntingt. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gagliardi, M., and Ashizawa, A.T. (2021). The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040433"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1021\/acs.molpharmaceut.0c01238","article-title":"Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System","volume":"18","author":"Kont","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_11","unstructured":"Mohammed, A.F.A., Motoyama, K., Higashi, T., and Arima, H. (2018). Cyclodextrin\u2014A Versatile Ingredient, InTech."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jconrel.2020.11.011","article-title":"Cyclodextrin Based Natural Nanostructured Carbohydrate Polymers as Effective Non-Viral SiRNA Delivery Systems for Cancer Gene Therapy","volume":"330","author":"Mousazadeh","year":"2021","journal-title":"J. Control Release"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1021\/mp3003946","article-title":"Self-Assembling Modified \u03b2-Cyclodextrin Nanoparticles as Neuronal SiRNA Delivery Vectors: Focus on Huntington\u2019s Disease","volume":"10","author":"Godinho","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102338","DOI":"10.1016\/j.cis.2020.102338","article-title":"Cyclodextrins and Inorganic Nanoparticles: Another Tale of Synergy","volume":"288","year":"2021","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejps.2015.02.007","article-title":"Synthesis and Characterization of Rabies Virus Glycoprotein-Tagged Amphiphilic Cyclodextrins for SiRNA Delivery in Human Glioblastoma Cells: In Vitro Analysis","volume":"71","author":"Gooding","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejpb.2021.11.003","article-title":"Modified Cyclodextrin-Based Nanoparticles Mediated Delivery of SiRNA for Huntingtin Gene Silencing across an in Vitro BBB Model","volume":"169","author":"Cronin","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1039\/D1RA00550B","article-title":"Application Progress of RVG Peptides to Facilitate the Delivery of Therapeutic Agents into the Central Nervous System","volume":"11","author":"Wang","year":"2021","journal-title":"RSC Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1523\/JNEUROSCI.6348-09.2010","article-title":"Impaired Ganglioside Metabolism in Huntington\u2019s Disease and Neuroprotective Role of GM1","volume":"30","author":"Maglione","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Chaves, G., Stanley, J., and Pourmand, N. (2019). Mutant Huntingtin Affects Diabetes and Alzheimer\u2019s Markers in Human and Cell Models of Huntington\u2019s Disease. Cells, 8.","DOI":"10.3390\/cells8090962"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin Expression in Patients with Huntington\u2019s Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eaar3959","DOI":"10.1126\/scitranslmed.aar3959","article-title":"Huntingtin Suppression Restores Cognitive Function in a Mouse Model of Huntington\u2019s Disease","volume":"3959","author":"Southwell","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1021\/cn3000372","article-title":"Click-Modified Cyclodextrins as Nonviral Vectors for Neuronal SiRNA Delivery","volume":"3","author":"Godinho","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"22137","DOI":"10.1038\/s41598-020-78790-5","article-title":"Analysis of Mutant and Total Huntingtin Expression in Huntington\u2019s Disease Murine Models","volume":"10","author":"Fodale","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","article-title":"Allele-Selective Transcriptional Repression of Mutant HTT for the Treatment of Huntington\u2019s Disease","volume":"25","author":"Zeitler","year":"2019","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1212\/NXG.0000000000000430","article-title":"Genotyping Single Nucleotide Polymorphisms for Allele-Selective Therapy in Huntington Disease","volume":"6","author":"Claassen","year":"2020","journal-title":"Neurol. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40259-022-00519-9","article-title":"Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic","volume":"36","author":"Rook","year":"2022","journal-title":"BioDrugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1002\/ejoc.201100445","article-title":"Efficient and Versatile Modification of the Secondary Face of Cyclodextrins through Copper-Catalyzed Huisgen 1,3-Dipolar Cycloaddition","volume":"2011","author":"Ward","year":"2011","journal-title":"Eur. J. Org. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.arcmed.2014.11.020","article-title":"Cyclodextrins, Blood-Brain Barrier, and Treatment of Neurological Diseases","volume":"45","author":"Fenyvesi","year":"2014","journal-title":"Arch. Med. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"107829","DOI":"10.1016\/j.exer.2019.107829","article-title":"Supramolecular Cyclodextrin Complex: Diversity, Safety, and Applications in Ocular Therapeutics","volume":"189","author":"Chaudhari","year":"2019","journal-title":"Exp. Eye Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.3762\/bjoc.12.261","article-title":"Interactions between Cyclodextrins and Cellular Components: Towards Greener Medical Applications?","volume":"12","author":"Leclercq","year":"2016","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2217\/nnm-2018-0139","article-title":"Nanoparticle Crossing of Blood-Brain Barrier: A Road to New Therapeutic Approaches to Central Nervous System Diseases","volume":"13","year":"2018","journal-title":"Nanomedicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"105076","DOI":"10.1016\/j.nbd.2020.105076","article-title":"Striatal Circuit Development and Its Alterations in Huntington\u2019s Disease","volume":"145","author":"Lebouc","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.msec.2017.12.029","article-title":"Targeted Transport of Nanocarriers into Brain for Theranosis with Rabies Virus Glycoprotein-Derived Peptide","volume":"87","author":"Fu","year":"2018","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Borroni, V., and Barrantes, F.J. (2021). Homomeric and Heteromeric A7 Nicotinic Acetylcholine Receptors in Health and Some Central Nervous System Diseases. Membranes, 11.","DOI":"10.3390\/membranes11090664"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.tcm.2008.11.007","article-title":"Endothelial Nicotinic Acetylcholine Receptors and Angiogenesis","volume":"18","author":"Cooke","year":"2008","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/1061186X.2016.1223676","article-title":"The Potential Use of Rabies Virus Glycoprotein-Derived Peptides to Facilitate Drug Delivery into the Central Nervous System: A Mini Review","volume":"25","author":"Huey","year":"2017","journal-title":"J. Drug Target."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/hmg\/dds397","article-title":"A Fully Humanized Transgenic Mouse Model of Huntington Disease","volume":"22","author":"Southwell","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41587-021-00987-4","article-title":"Questions Swirl around Failures of Disease-Modifying Huntington\u2019s Drugs","volume":"39","author":"Sheridan","year":"2021","journal-title":"Nat. Biotechnol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/2\/520\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:23:47Z","timestamp":1760120627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/2\/520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["pharmaceutics15020520"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15020520","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]}}}